Category: Corona Virus Vaccine

Page 85«..1020..84858687..90100..»

UC Irvine researchers shine light on deceptive COVID-19 treatments – OCRegister

October 27, 2023

IRVINE A UC Irvine study published Thursday in a science journal showed that last year 38 business in North America marketed unproven stem cell therapies and exosome products to treat or prevent COVID-19.

The businesses operated or had ties to 60 clinics 24 in the United States and 22 in Mexico, with the rest in Guatemala, Malaysia, Poland and Spain, according to the study published in Stem Cell Reports.

The businesses touted treatments long-COVID and immune boosters to prevent or treat infection.

The scientists involved in the study said such untested treatments can pose health hazards such as minor complications to more serious afflictions like pumonary embolisms, cardiovascular issues and acute bacterial infections. The treatments dont come cheap either with costs ranging from $2,950 to $25,000, which are not covered by insurers.

Patients suffering from long COVID are the primary marketing target of businesses engaged in direct-to-consumer advertising of stem cells and exosome products for COVID-19, the scientists wrote in the study. It is understandable that individuals seeking relief from shortness of breath, fatigue, brain fog, heart palpitations, loss of smell and other symptoms search for interventions that might help them.

Those afflicted with lingering symptoms of COVID-19 are vulnerable to having their suffering, desperation and hope exploited by entities making appealing therapeutic claims without having the scientific evidence needed to make such representations, the studys authors wrote. Likewise, there is no current scientific consensus that stem cell interventions and exosome products can reliably prevent individuals from being infected by SARS-CoV-2 or boost their immune systems in such a manner that their risk of infection is reduced. Such marketing claims are distinct from translational research efforts that have responded to the pandemic by generating meaningful safety and efficacy data for specific stem cell interventions and exosome products.

Leigh Turner, professor of health, society and behavior in UCIs Program in Public Health and an author of the study said the exploitation of those suffering from long COVID is very alarming, because these people are not accessing evidence-based treatments that have been reviewed and approved by national regulators. When going online looking for stem cell or exosome treatments, people need to be alert to the possibility of scams.

The studys authors were struck by the fact that two dozen of the clinics were U.S.-based because federal agencies have been issuing warning letters to companies that mislead consumers about unproven stem cell and exosome products.

But some of the businesses stop the marketing when they get a warning letter while others dodge regulators with new clinics opening.

Turner recommended further regulatory oversight, research, testing and approval of stem cell treatments and exosome therapies for COVID-19.

Continued here:

UC Irvine researchers shine light on deceptive COVID-19 treatments - OCRegister

WCSD and CHA to Offer Flu and COVID-19 Vaccine Clinics – KTVN

October 27, 2023

Community Health Alliance (CHA) will be hosting flu and COVID-19 vaccine clinics at various Washoe County School District (WCSD) schools in October and November.

Vaccines will be available for students 5-years-old and above.

A parent or legal guardian must be present for students to receive a vaccine, and guardians are asked to bring an identification card and health insurance card if applicable.

Most health insurance plans cover the cost of vaccines.

For those who are uninsured, CHA's community health partners Adobe Population Health, Anthem, Immunize Nevada, and Molina Healthcare of Nevada are offering free vaccines while supplies last.

Below is the vaccine clinic schedule:

For children under the age of four, or people who can not attend the clinics, guardians can call 775-329-6300 to make an appointment at Community Health Alliance.

Appointments can also be made online at chanevada.org

(CHA assisted with this report.)

View post:

WCSD and CHA to Offer Flu and COVID-19 Vaccine Clinics - KTVN

1 in 20 UK long-COVID patients still reported symptoms at 1 year – University of Minnesota Twin Cities

October 27, 2023

Adult long-COVID patients in England reported worse mental health and related quality of life than those who were never infected or recovered from their infections, suggests a study yesterday in Nature Communications.

Imperial College London researchers analyzed self-reported mental health and quality of life among 276,840 participants from August to December 2022.

The team also used data from a follow-up survey of participants in the REal-time Assessment of Community Transmission-2 study, which included six rounds of random samples of the population to evaluate community prevalence of SARS-CoV-2 antibodies in England.

Overall, 59.1% of participants had tested positive for COVID-19.Symptoms among 130,251 respondents lasted for, on average, 5.4 weeks (range, 1 day to 3 years). In total, 7.5% and 5.2% reported symptoms for at least 12 weeks (long COVID) and 52 weeks or longer (very long COVID), respectively.

Risk factors for long or very long COVID included female sex (adjusted odds ratio [aOR], 1.42 and 1.49, respectively), having at least one underlying condition (aOR, 1.31 and 1.52), and moderate or severe COVID-19 (aOR, 1.76 and 1.47).

Although COVID-19 is usually of short duration, some adults experience persistent and burdensome illness, although a sizeable proportion still recover after a prolonged period.

The probability of long COVID and very long COVID was lower in Asian than in White people (aOR, 0.80 and 0.71, respectively) and in those infected during the Alpha (aOR, 0.60 and 0.59), Delta (OR, 0.38 and 0.32), or Omicron waves (OR, 0.12 for long COVID; insufficient follow-up time for very long COVID) than in those with wild-type infections.

The most common ongoing symptoms were mild fatigue (66.9%), difficulty thinking or concentrating (54.9%), and joint pain (54.6%). The greatest difference in symptom prevalence between those with ongoing symptoms and other participants were for altered smell (aOR, 9.31) or taste (aOR, 8.47), shortness of breath (aOR, 6.69), severe fatigue (aOR, 6.19), difficulty thinking or concentrating (aOR, 4.97), chest tightness or pain (aOR, 4.71), and memory loss (aOR, 4.40).

"Although COVID-19 is usually of short duration, some adults experience persistent and burdensome illness, although a sizeable proportion still recover after a prolonged period," the authors wrote.

See the original post:

1 in 20 UK long-COVID patients still reported symptoms at 1 year - University of Minnesota Twin Cities

Ken Shamrock never doubted Valor Bare Knuckle would return after COVID-19 shutdown – MMA Fighting

October 27, 2023

Ken Shamrocks bare-knuckle boxing promotion is back on track.

The MMA pioneers Valor Bare Knuckle returns Friday with VBK 2, which takes place at the University of North Florida in Jacksonville, Fla. The event is Valors first show since its 2019 debut, a hiatus triggered by the 2020 COVID-19 shutdown.

Despite seeing the promotions momentum sputter amid the pandemic, Shamrock told MMA Fighting he and his team never considered shutting it down for good.

Never, ever, ever thought we werent coming back, Shamrock said. Never. We were always working behind the scenes, building structure within our business while creating apps through which we could stream our fights. Theres a lot of stuff that weve been doing. Obviously, in my mind, experiencing the fan base, even experiencing early on when I was just fighting in the back of bars, not a lot of people there, its just not the same if you dont have a fan base and your business is out there giving fans something they want to see.

We waited for a time to come back, he continued. Obviously, this is fight where theres a lot of fans going to Florida that weekend with the Florida-Georgia game. I think its a great opportunity for people that are there to have a great weekend, come out and watch the fights on weekend, go watch Florida-Georgia college football on Saturday, and then to close it all off, Sunday NFL football. So its a great weekend. I know thats what Im doing. But yeah, when they come out and look at the ring sets, the belts, Oct. 27 at the UNF Arena in Jacksonville, were going to have some great fights, and theres going to be some fun that night.

Considering how the aftermath of VBK 1 went, Shamrock was due for a bit of luck. He hopes that the second event benefits from a major sports weekend in Jacksonville. His team initially considered moving away from the crowded slate when the schedule materialized, but they later decided it was a blessing and not a curse.

Plans ended up changing anyway with one fighter bowing out of Fridays main event. Lavar Johnson was originally scheduled to fight Mark Godbeer, but MMA lifer Travis Wiuff stepped in for Godbeer to face his fellow cagefighting veteran.

This is a big opportunity for Johnson, who lived up to his reputation as a knockout artist at VBK1 with a 27-second drubbing of James McSweeney. He is now poised to be one of the names the promotion can build around.

First of all, hes just a great individual, Shamrock said of Johnson. A guy whos overcome adversity. He went through some hard times early on, just like myself, I went through some really tough times. To be able to see somebody be able to change their life and be able to get back on the right track again is also always golden. You love to see that, but I think as a fighter I just love how he actually carries himself. Hes respectful, but hes dangerous, and he has absolutely no thoughts about going in there and just knocking the p*** out of you. But outside the ring, hes an absolute gentleman, so I really like that about him.

But again, I tell people, do not look past this because this guys a beast. He may be a little bit older, but this guys got power, and he touches you, youre doing down.

Johnsons punching power has always been respected, with 17 of his 18 MMA wins coming by way of knockout, including memorable first-round finishes of Pat Barry and Joey Beltran. He showed little in the way of an all-around game, which put a clear ceiling on his fighting career. But he looked like a natural fit for the world of bare-knuckle boxing when he debuted against McSweeney.

Shamrock agreed with the suggestion that Johnson, who previously competed for Bellator and UFC, might have become a bigger star if hed had the option of doing bare-knuckle.

Absolutely, Shamrock said. I think theres a lot of guys you see, just regular boxers, that havent really been able to do well, theyre average in there, but they have this knockout power. Theres guys like myself, guys that have that beast mode and power and you literally just destroyed someone, but because they landed more punches, they get the win. That power literally changes everything for the larger guys that are the true beasts.

A veteran of 101 documented MMA fights, Wiuff is perfectly poised to play the spoiler against Johnson. Diesel has seen it all in his combat sports career, having fought his way across the U.S. for the past 22 years. Shamrock warns Wiuff is definitely not to be underestimated.

Hes smart, Shamrock said. He knows when to turn it on, when not to turn it on. He knows when to move, and hes a smart fighter. He has a lot of tools to bring out against Lavar and hes going to have to, because I think Lavar is just going to be going for that knockout. If he doesnt, Travis is capable of doing it.

Just being able to move and set up his punches, it could be a problem for Lavar because Lavar isnt that experienced when it comes to that movement. Hes more of that straightforward, big punches. So if Travis comes out and fights smart, this is going to be a very, very good fight.

Tickets are available now for VBK 2 and a live stream airs Friday on the Valor BK official website (free subscription required) beginning at at 7 p.m. ET.

Read more

Read this article:

Ken Shamrock never doubted Valor Bare Knuckle would return after COVID-19 shutdown - MMA Fighting

COVID-19 and Dobbs Spur Surprising Increase in Abortion Pill Access – Ms. Magazine

October 27, 2023

The abortion drug Mifepristone, also known as RU486, is pictured in an abortion clinic February 17, 2006 in Auckland, New Zealand. (Photo by Phil Walter/Getty Images)

A version of this article originally appeared in the Daily Hampshire Gazette.

In nations banning abortion across the world, activists have created community support networks facilitating access to abortion pills. In June 2022, when the Supreme Court eliminated constitutional abortion rights in Dobbs v. Jackson Womens Health Organization and many states banned abortion, U.S. activists were ready to create their own alternative supply systems for abortion pills.

Over the last several years, in anticipation of the Supreme Court overturning Roe v. Wade and in response to the Covid pandemic, activists developed interstate telemedicine abortion services and community support networks that are now providing abortion pills to people living in all 50 states, including states with bans. As a result, abortion pills are now more accessible and affordable than ever before.

Two medications are used for early abortion: mifepristone, which blocks the effects of the pregnancy-sustaining hormone progesterone; and misoprostol, a commonly-used ulcer medication that causes contractions to expel pregnancy tissue. Used in combination, these medications are 98 percent effective in the first 12 weeks of pregnancy and safer than Tylenol.

Before COVID-19, abortion pills were hard to access and expensive. Despite being safe and easy to use, the abortion pill mifepristone was more heavily restricted than opioids. The FDA allowed only certified physicians to dispense abortion pills, which they were required to do in personan unusual and medically unnecessary requirement. These restrictions combined with an expensive medical system meant that patients had to pay an average of $560 for an abortion with pills at U.S. clinics, despite the fact that the pills are used at home and cost only two to three dollars per dose to manufacture.

During COVID-19, reproductive health advocates challenged these FDA restrictions in court, leading to a shift in FDA policy to allow telemedicine abortion for the first time. As a result, clinicians could prescribe the medication remotely and mail abortion pills to patients for a much lower cost. Telemedicine abortion clinics quickly sprouted up in about half of states.

After Dobbs, several states passedtelemedicine abortion provider shield laws that allowed clinicians licensed in those states to provide telemedicine abortion to people living in any state. With these new protections, telemedicine abortion providers began serving patients in states with abortion bans.

One interstate telemedicine abortion clinic, Aid Access, recently reported they are mailing abortion pills to 5,500 people living in states with abortion bans each month. Whereas before COVID-19, patients had to travel hundreds of miles to brick-and-mortar clinics, walk a gauntlet of protesters and pay on average $560 for medication abortion, now they can obtain these pills from the privacy of their own homes for a sliding scale fee of up to $150 in all 50 states.

Access to these safe and easy-to-use medications has increased outside of the medical system as well. In response to new abortion bans,community support networkssuch as Red State Access, Las Libres, AccessMA, and WeSaveUs began sending free abortion pills to people living in states banning abortion. Meanwhile, increased demand led to a proliferation of websites selling pills, which dropped their prices from hundreds of dollars before Dobbs to as low as $37 per dose today.

The creative actions of reproductive health advocates in response to COVID-19 and Dobbs have ripped away decades of political and medical red tape and finally placed abortion pills directly in the hands of people who need them.

Information about these community support networks and vetted websites selling pills is readily available from the organization Plan C, which conducts research and publicly shares information about how people are accessing abortion pills in the United States. Confidential support services have developed, including the Miscarriage +Abortion Hotline with medical professionals ready to assist people using abortion pills, the Reprocare Healthline providing logistical and emotional support, and the Repro Legal Hotline available to answer legal questionsall at no charge. People can also find support at the abortion subreddit run by OARS, the Abortion Online Resource Squad. A new online chatbot namedCharleyhelps abortion seekers in all 50 states find quick, accurate and confidential abortion information, tailored to their individual needs and circumstances.

These seismic changes in abortion pill access have broken through decades of political and medical barriers that have limited access to abortion pills. The climate of fear and intimidation created by the anti-abortion movement led to overregulation of this safe and easy-to-use medication and few clinicians willing to navigate these burdensome restrictions, which blocked increased access and drove up prices. New pathways for accessing abortion pills spurred by COVID-19 and Dobbs have finally freed mifepristone from the vise grip ofthese unjust political and medical barriers.

Anti-abortion extremists are now trying once again to limit access to abortion pills in a lawsuit currently on appeal at the Supreme Court, but the cat is out of the bag. Even if they win this lawsuit, the robust alternative supply networks established in the wake of Dobbs will persist. The creative actions of reproductive health advocates in response to COVID-19 and Dobbs have ripped away decades of political and medical red tape and finally placed abortion pills directly in the hands of people who need them.

Read more:

See the article here:

COVID-19 and Dobbs Spur Surprising Increase in Abortion Pill Access - Ms. Magazine

Estimation of SARS-CoV-2 IgG Antibodies in Healthcare Worker-Administered Covishield and Covaxin Vaccines at a … – Cureus

October 25, 2023

Specialty

Please choose I'm not a medical professional. Allergy and Immunology Anatomy Anesthesiology Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health Family Medicine Forensic Medicine Gastroenterology General Practice Genetics Geriatrics Health Policy Hematology HIV/AIDS Hospital-based Medicine I'm not a medical professional. Infectious Disease Integrative/Complementary Medicine Internal Medicine Internal Medicine-Pediatrics Medical Education and Simulation Medical Physics Medical Student Nephrology Neurological Surgery Neurology Nuclear Medicine Nutrition Obstetrics and Gynecology Occupational Health Oncology Ophthalmology Optometry Oral Medicine Orthopaedics Osteopathic Medicine Otolaryngology Pain Management Palliative Care Pathology Pediatrics Pediatric Surgery Physical Medicine and Rehabilitation Plastic Surgery Podiatry Preventive Medicine Psychiatry Psychology Pulmonology Radiation Oncology Radiology Rheumatology Substance Use and Addiction Surgery Therapeutics Trauma Urology Miscellaneous

Read the rest here:

Estimation of SARS-CoV-2 IgG Antibodies in Healthcare Worker-Administered Covishield and Covaxin Vaccines at a ... - Cureus

Factors associated with COVID-19 vaccination among pregnant … – Nature.com

October 25, 2023

Study setting, study design, and population

This retrospective cohort study used linked data from the live birth and vaccination information systems in Rio de Janeiro city. Rio de Janeiro is the second largest city in Brazil, with an estimated population of 6,700,000. It has a monthly per capita income of 4 minimum wage, considered a high-income city compared to other regions of the country37 In 2021, the number of live births was 67,97338. In July 2022, the coverage of COVID-19 vaccination was 89% for the complete primary regimen and 57% for a booster dose in the general population above 18 years39.

The COVID-19 immunisation started in Rio de Janeiro city on January 20, 202140, initially for healthcare professionals, adults older than 60 years, and high-risk groups. Pregnant women with comorbidities started vaccination in March 2021; by May 2021, it was interrupted due to a severe adverse event related to the COVID-19 vaccine in this population. From July 07, 2021, vaccination was resumed and made available for all pregnant, breastfeeding or women planning to become pregnant41. CoronaVac (Sinovac/Butantan) and BNT162b2 (Pfizer/Biotech) were the recommended platforms.

For this investigation, we included all women who delivered live births in Rio de Janeiro city between 1st August 2021 and 31 July 2022. Our exclusion criteria were multiple births, ages less than 18 years or higher than 49 years, and records with missing or implausible gestational ages (> 44 weeks) (Fig. 2).

The Declaration of Live Birth, a legal document filled out by the health care professional who attends the birth, is entered into the Live Birth Information System (SINASC). It contains details on the mother (such as age, education, skin colour, and marital status), about the pregnancy (such as antenatal appointments, the gestational period, prior gestations, previous live births, and previous losses), and details about the newborn (e.g., birth weight, sex, APGAR score). In addition, all vaccinations provided in Brazil are documented in the National Immunization Program Information System (SI-PNI), along with the administration date of the first, second, and booster doses, with its platform type. The SINASC data initially available had records from women who gave a live birth in Rio de Janeiro city from January 1, 2020, to August 28, 2022. The SI-PNI data included vaccination records from January 19, 2021, to August 31, 2022 (Supplementary Figure 1, Table 1 and Table 2). The linkage between records from SI-PNI and SINASC allowed access to any vaccination that happened before, during and after the pregnancy period.

The matching process used the maternal name, date of birth, zip code, and neighbourhood. We used the Jaro-Winkler string comparator to compare the similarity between string variables recorded in SINASC and SI-PNI. This algorithm calculates the similarity between two strings based on the number of shared characters and transpositions42. The resulting similarity score ranges between 0 (no similarity) and 1 (perfect similarity). We categorised the similarity scores into three categories: (0, 0.85), (0.85, 0.95), and (0.95, 1)]. We employed a three-step approach that checked for a string similarity score greater than 0.95, followed by exact matches for dates of birth and zip code. Any potential matches then underwent a manual review. After data linkage, the individual identifiers were removed, and the de-identified dataset was made available for analysis.

We estimated the date of the last period (DLP) using the date of delivery minus the days of pregnancy according to the gestational age at birth. We determined the date of conception by adding 14 days to the DLP. We defined the gestational period as the time between the date of conception and the date of birth. The vaccination status was determined using the dates of the vaccination registries compared to the gestational period.

Women who received at least one dose between the conception date and the date of delivery were considered vaccinated during pregnancy. Those who received all registered doses before the pregnancy period (before the conception date) were grouped as vaccinated before pregnancy. Those who received vaccines exclusively after the delivery date were assigned as vaccinated after pregnancy. Finally, women with no register of a vaccine dose were regarded as never vaccinated. We estimated vaccine uptake during pregnancy as the proportion of women who received any vaccination during pregnancy as a percentage of all births (Supplementary Table 3).

We divided variables into sociodemographic: age (1824, 2534, 35 years), education (07, 811, 12 years), self-identified skin colour (black, parda/brown, white, Asian, or Indigenous), and marital status (with or without a partner). And obstetric: the trimester of the first antenatal care appointment (first, second, or third), the total number of appointments (03, 46, or >6), the number of previous gestations (none, 12, or 3), the number of previous live births (none, 12, or 3), and the number of previous child loss (none or at least one). The Indigenous and Asian races were presented in the descriptive analysis and excluded from the logistic regression due to the small sample size.

We considered the length of pregnancy and the burden of COVID-19 infection during the study period to be a confounder a priori. Therefore, we included the month-year of birth and the gestational week at delivery as additional variables in the analyses.

We assessed each groups characteristics by describing categorical variables as frequencies and percentages, excluding missing data. Continuous variables, such as age and gestational age, were presented as the median and interquartile range (IQR). In the descriptive analysis, we stratified the groups by being vaccinated only before pregnancy, vaccinated with at least one dose during pregnancy, and never vaccinated.

To identify the factors associated with vaccine uptake in pregnant women, we compared only the population of women vaccinated during pregnancy with those who were never vaccinated during the study period. For each potential factor associated with uptake, we ran a bivariate logistic regression individually, describing the crude odds ratio (OR) and its associated 95% confidence interval, controlled by gestational age and month-year of birth (Supplementary Table 7).

In addition, we performed a multiple logistic regression using a hierarchical framework with two levels. In the first level, we had the socioeconomic variables: age, education, self-identified skin colour, and marital status. In the second level, we included all the variables above and the obstetrics variables: the total number of antenatal appointments, the number of previous live births, and the number of previous child losses.

In the first model of multiple logistic regression, we included only the socioeconomic variables. The overall effect of socioeconomic factors (the distal factors) was assessed in this model 1. In the second model, we included the obstetric variables in addition to the sociodemographic block. Therefore, the unconfounded effect of the obstetric variables was obtained in this model. Both models were also controlled by gestational age and month-year of birth. Missing data on each covariate were excluded from the analysis (Supplementary Table 8). The final adjusted odds ratio and 95% confidence intervals were described for each model separately (Supplementary Table 7). Data management and statistical analysis were conducted using IBM SPSS, Statistical Package for the Social Sciences, Version 28.0 (Armonk, NY: IBM Corp). The de-identified dataset and the programming codes can be made available under the request.

The present study has been approved by the Ethics Committee of Research Center Gonalo Moniz /Oswaldo Cruz Foundation, Salvador, Bahia, Brazil (IORG 0002090/OMB No. 0990-0279 valid until 01/27/2025), under the Certificate of Submission for Ethics Review No 63287822.0.0000.0040. The protocol and procedures presented in the project are in full accordance with the Brazilian legislation (Resolution CNS 466/2012) and the declaration of Helsinki regarding ethical standards in conducting research involving human beings. Due to the retrospective nature of the study, the need for informed consent was waived by the Ethics Committee of Research Center Gonalo Moniz /FIOCRUZ/BA.

See the original post:

Factors associated with COVID-19 vaccination among pregnant ... - Nature.com

FTC Takes Action Against Makers of an ‘Invisible Mask’ They Falsely … – Federal Trade Commission News

October 25, 2023

The Federal Trade Commission sued to stop four related defendants from deceptively marketing their 1 Virus Buster Invisible Mask

(Invisible Mask) that purportedly creates a three-foot barrier of protection against 99.9 percent of all viruses and bacteria, including COVID-19 without any scientific proof that the product actually works.

Despite receiving a warning letter that the FTC sent in July 2020, the New York-based defendants continued falsely advertising the Invisible Maska badge worn around the neckas a scientifically proven defense against COVID-19 and other diseases and that it was a government-approved device, according to the FTCs complaint.

Three of the four defendants have agreed to a proposed ordersettling the FTCs complaint, and will be banned from making unsupported health claims for products designed to prevent or treat COVID-19.

The defendants claims that their products can stand in for approved COVID-19 vaccines are bogus, said Samuel Levine, Director of the FTCs Bureau of Consumer Protection. The FTC will use every tool it has at its disposal to stop false and unsubstantiated health claims that endanger consumers.

The complaint alleges defendants Gary Kong, Timothy Wetzel, and the two companies they operate, K W Technology Inc. and K W Technology NV Inc., violated the FTC Act and the Covid Consumer Protection Act through their marketing and sale of the Invisible Mask on their own website, YouTube, and Facebook, where it was called The 1 Virus Buster Card.

This card, which was worn around the neck or clipped onto clothing, was sold using deceptive claims, the FTC says. For example, the defendants claimed their product uses quantum theory technology, combines known virus and bacteria killing compounds. It is safe, simple, and effective. All you need to do is hang it around your neck or attach it to your collar, close to your mouth and nose. . . it kills 99.9% of most harmful bacterial and viruses . . . within a three-foot radius.

The FTC contends the defendants have no reliable scientific evidence to support their claims that the Invisible Mask can prevent any human disease, and that despite contacting the FTC after receiving the warning letter and vowing to stop making such claims, they simply continued deceptively marketing the product.

The complaint also alleges the defendants falsely claimed that the Invisible Mask or its materials are government approved or made in a government-approved facility. They also falsely claimed the Invisible Mask had FDA Approval and that that the materials used to make it are EPA-approved. On their website the defendants posted a phony Certificate of Registration with the FDAs logo, despite the fact that no such agency certificate exists.

Three of the defendants have agreed to settle the FTCs complaint in this case. A proposed court order will ban defendants Kong and his two companies, K W Technology Inc. and K W Technology NV Inc., from advertising, promoting, or selling any product claiming to prevent or treat COVID-19, unless the claims are true and supported by scientific evidence. The order also will bar the defendants from making any health-related product claims unless they have scientific evidence that the claim is true and from making misrepresentations about products health benefits, performance, efficacy, safety, or side effects.

The order also prohibits the defendants from misrepresenting they have government approval, clearance, or authority for their products and product claims. Finally, it requires the payment of $150,000.

The Commission voted 3-0 to file the complaint and proposed stipulated order against defendants Kong, K W Technology Inc. and K W Technology NV Inc. The FTC filed the documents in the U.S. District Court for the Eastern District of New York. Litigation continues against defendant Wetzel, who did not agree to the proposed settlement.

The lead attorney on the matter is Robin L. Rock of the FTCs Southeast Region.

Continued here:

FTC Takes Action Against Makers of an 'Invisible Mask' They Falsely ... - Federal Trade Commission News

Intestinal fungi may worsen lung inflammation in severe COVID-19 … – University of Minnesota Twin Cities

October 25, 2023

Stephanie Rossow / CDC

In severely ill COVID-19 patients, some kinds of fungi can thrive in the intestines, exacerbating the virus's characteristic inflammation and leading to an outsized immune response against the fungi for up to 1 year after infection, suggests a study published yesterday in Nature Immunology.

Weill Cornell Medicine and New York Presbyterian researchers analyzed blood samples from patients with severe COVID-19, finding immunoglobulin G (IgG) antibodies against fungi commonly found in the gut and an increase in neutrophil immune cells in the lungs.

They then used mouse models to confirm that fungi in the gut, especially strains of Candida albicans yeast, provoked the production of more neutrophils in the blood and lungs. The mice also had signs of inflammation when infected with SARS-CoV-2.

Patient blood samples showed signs of persistent immune-system changes believed to be related to long COVID. At 1 year postinfection, the blood still contained antifungal antibodies, and stem cells that give rise to neutrophils were primed to attack fungi.

Severe and long COVID-19 were not thought to involve fungal blooms in the intestines that, in addition to the virus, can impact patients immunity.

The immune protein interleukin-6, induced by fungi, seemed to increase levels of both neutrophils in the lungs and fungal antibodies. The use of IL-6 blockers or antifungal drugs in patients or mice, however, reduced levels of neutrophils and fungal antibodies. Patients treated with the anti-inflammatory drug tocilizumab saw sustained reductions in IgG antibodies against both C albicans and neutrophil progenitors.

"Severe and long COVID-19 were not thought to involve fungal blooms in the intestines that, in addition to the virus, can impact patients immunity," senior author Iliyan Iliev, PhD, of Weill Cornell Medicine, said in a college news release.

The authors said the findings don't change the guidelines for treating severe or long COVID, but they may someday lead to tailored treatment, such as the use of antifungal antibodies to identify patients eligible for a therapy targeting the fungi or the immunologic changes they trigger. The antifungal antibodies may also be a marker of increased risk of long COVID or other infectious inflammatory conditions.

See more here:

Intestinal fungi may worsen lung inflammation in severe COVID-19 ... - University of Minnesota Twin Cities

Page 85«..1020..84858687..90100..»